Edwards Lifesciences
773 hedge funds and large institutions have $19.6B invested in Edwards Lifesciences in 2017 Q4 according to their latest regulatory filings, with 113 funds opening new positions, 266 increasing their positions, 273 reducing their positions, and 77 closing their positions.
47% more first-time investments, than exits
New positions opened: 113 | Existing positions closed: 77
30% more funds holding in top 10
Funds holding in top 10: 10 → 13 (+3)
4% more funds holding
Funds holding: 740 → 773 (+33)
2% more capital invested
Capital invested by funds: $19.3B → $19.6B (+$291M)
0% more call options, than puts
Call options by funds: $106M | Put options by funds: $106M
3% less repeat investments, than reductions
Existing positions increased: 266 | Existing positions reduced: 273
4.47% less ownership
Funds ownership: 250.95% → 246.47% (-4.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$262M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$94.3M |
| 3 |
Two Sigma Advisers
New York
|
+$84M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$74.3M |
| 5 |
Two Sigma Investments
New York
|
+$64.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECU
Egerton Capital (UK)
London,
United Kingdom
|
-$146M |
| 2 |
Legal & General Group
London,
United Kingdom
|
-$122M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$106M |
| 4 |
Renaissance Technologies
New York
|
-$104M |
| 5 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$74.8M |
EW Hedge Fund Activity: Q4 2017 in Review
773 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2017, worth a combined $19.6B — up 1.5% from $19.3B a quarter earlier.
Buyers outnumbered sellers: 113 funds opened new EW positions and 77 closed out — a net gain of 36 holders — while 266 added to existing stakes and 273 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $262M. The largest seller was Egerton Capital (UK), exiting entirely with an estimated $146M sold.
- 773 institutional investors held Edwards Lifesciences (EW) as of Q4 2017, up from 740 in Q3 2017.
- Funds reported $19.6B of Edwards Lifesciences stock for Q4 2017, up 1.5% quarter-over-quarter.
- 113 funds opened new Edwards Lifesciences positions in Q4 2017 and 77 closed out, a net change of +36 holders.
- The largest Edwards Lifesciences buyer in Q4 2017 was Bank of New York Mellon, an estimated $262M added.
- The largest Edwards Lifesciences seller in Q4 2017 was Egerton Capital (UK), an estimated $146M sold.
Based on aggregated 13F filings for Q4 2017.